Company intelligence / Profile preview
Longevity Biotech
Philadelphia, Pennsylvania, United Stateslongevitybiotech.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
Longevity Biotech has developed a proprietary Hybridtide™ platform to create metabolically stable and structurally enhanced synthetic peptides for disease-modifying therapies. Their lead candidate, LBT‑3627, targets immune rebalancing in Parkinson’s Disease and has entered clinical trials. The company reports support from major foundations and government agencies but does not yet have published late-stage results[1][5][6].
- Therapeutic areas
- Neurology
- Modalities
- Synthetic peptides (Hybridtides™)Peptidomimetics
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
Michael J. Fox FoundationNational Multiple Sclerosis SocietyNational Institutes of HealthNational Science Foundationunspecified global development partners
Beyond the preview
Go deeper on Longevity Biotech.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Longevity Biotech.